NewsRelease

ResearchArticle Highlights Advantageous Use Of AlbuVoid™ in ClinicalProteomics 

MONMOUTHJUNCTION, NJ,March1, 2019 -- BiotechSupport Group reports on a new research report which highlights thesimplicity and efficiency of their Albumin depletion samplepreparation technology as an enrichment step for clinical research ofhuman serum using LC-MS proteomic analysis. The citation is: 

Vialaret,Jerome & Kadi, Sarah & Tiers, Laurent & O Flynn, Robin &Lehmann, Sylvain & Hirtz, Christophe. (2018). Albumin depletionof human serum to improve quantitative clinical proteomics. CurrentTopics in Peptide & Protein Research19. 53-62.

http://www.researchtrends.net/tia/abstract.asp?in=0&vn=19&tid=26&aid=6192&pub=2018&type=3

Proteinsare essential for biomarker and disease discovery though the mostabundant proteins often provide very limited clinically relevantdata, as can be the case for albumin or immunoglobulins. In thiswork, the investigators focused on depleting albumin from human serumsamples using an albumin depletion and low abundance proteinenrichment kit – AlbuVoid™, which enabled the detectionof several low-abundance proteins. By employing an optimizedprotocol, enriched proteins known asbiomarkers for various diseases were identified. The article states“Protein capture was performed using AlbuVoid™ Kit onserum samples… For the LCMS analysis, elution was madedirectly on the beads with denaturant solution (30 μL of 8 M urea/ 20 mM DTT / 100 mM Tris pH 8.5) before tryptic digestion. Incomparison, methods using antibodies needed at least one-half daymore. The albumin depletion method allowed to save precious time.”.The authors concluded that the AlbuVoid™ depletion methodproved to be faster and more cost-effective than antibody basedmethods, and could be helpful for biomarker enrichment and detectionin medical research.

“Throughoutour product and methods development efforts, we have been especiallyfocused on overcoming the challenges of clinical proteomics. So I amare very pleased to see that AlbuVoid™ was advantageously usedfor this purpose. Because we use a porous silica bead surfacechemistry, the strong denaturing conditions studied here as the beadeluent. can provide a seamless workflow to FASP type digests.Consequently, the versatility of digest conditions, either FASP oron-bead digest - what we call BASP™, can offer many workflowand unique digest efficiency options. Collectively we continue tofind new benefits for clinical discovery and targeted proteomics.”states Swapan Roy, Ph.D., President and Founder of Biotech SupportGroup.

Formore information onAlbuVoid™,go to:http://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm

Formore information on the BSG complete line ofAlbumin& IgG Removal products,visit:https://www.biotechsupportgroup.com/Articles.asp?ID=451

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ forlipid adsorption, HemogloBind™ and HemoVoid™ forhemoglobin removal, and NuGel™ for functional proteomics. Fromthese innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com.

ForBusiness Development,Contact:

MattKuruc 732-274-2866, [email protected]